LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Închisă

SectorSănătate

24.04 2.47

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

23.18

Maxim

24.25

Indicatori cheie
By Trading Economics
Venit	10M 17M
Vânzări	30M 130M
EPS	0.13
Marjă de profit	13.432
Angajați	354
EBITDA	11M 22M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+47.94% upside

Statistici piață
By TradingEconomics
Capitalizare de piață	-285M 2.9B
Deschiderea anterioară	21.57
Închiderea anterioară	24.04

Sentimentul știrilor

By Acuity

66%

34%

305 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

12.42 / 14.93 Suport & Rezistență

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 mai 2026, 23:41 UTC

Câștiguri

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mai 2026, 21:40 UTC

Câștiguri

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mai 2026, 23:13 UTC

Câștiguri

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mai 2026, 23:13 UTC

Câștiguri

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mai 2026, 23:12 UTC

Câștiguri

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mai 2026, 23:11 UTC

Câștiguri

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:07 UTC

Câștiguri

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mai 2026, 23:06 UTC

Câștiguri

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mai 2026, 23:06 UTC

Câștiguri

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mai 2026, 23:05 UTC

Câștiguri

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mai 2026, 23:04 UTC

Câștiguri

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mai 2026, 22:50 UTC

Câștiguri

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mai 2026, 22:11 UTC

Câștiguri

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mai 2026, 22:11 UTC

Câștiguri

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mai 2026, 21:58 UTC

Câștiguri

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:47 UTC

Market Talk

Câștiguri

Costco Posts 13% Sales Growth in April -- Market Talk

6 mai 2026, 21:46 UTC

Câștiguri

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mai 2026, 21:40 UTC

Câștiguri

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mai 2026, 21:32 UTC

Acțiuni populare

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mai 2026, 21:29 UTC

Câștiguri

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

47.94% sus

Prognoză pe 12 luni

Medie 34.75 USD 47.94%

Maxim 36 USD

Minim 33 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

12.42 / 14.93Suport & Rezistență

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

305 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.